Abrupt cessation of one-year clopidogrel treatment is not associated with thrombotic events

Nina Djukanovic1, Zoran Todorovic, Slobodan Obradovic

  • 1Department of Cardiology, Institute for Cardiovascular Diseases, Clinical Centre of Serbia, Serbia.

Insights

Discontinuing one year of clopidogrel therapy after coronary stent implantation showed a low rate of thrombotic events. Platelet aggregation increased with adenosine diphosphate and arachidonic acid, but not thrombin receptor activating peptide.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Dual antiplatelet therapy with aspirin and clopidogrel is standard after coronary stent implantation.
  • The optimal duration of clopidogrel therapy and the risks of its discontinuation require further investigation.

Purpose of the Study:

  • To evaluate the incidence of thrombotic events after one year of clopidogrel discontinuation in patients with coronary stents.
  • To assess changes in platelet aggregability following clopidogrel cessation.

Main Methods:

  • Prospective, multicenter study of 200 patients treated with aspirin + clopidogrel for one year post-stent.
  • Platelet aggregation measured using adenosine diphosphate with PGE(1) (ADPHS), arachidonic acid (ASPI), and thrombin receptor activating peptide (TRAP) at baseline and 10, 45, 90 days post-cessation.
  • Six-month follow-up for thrombotic events.

Main Results:

  • A low incidence of thrombotic events (1%) was observed, including one ischemic stroke and one myocardial infarction.
  • Platelet aggregation induced by ADPHS and ASPI significantly increased 10-90 days after clopidogrel cessation (P < 0.001).
  • TRAP-induced platelet aggregation remained unchanged throughout the study period.

Conclusions:

  • The risk of thrombotic events after one year of clopidogrel discontinuation in patients with coronary stents may be lower than anticipated.
  • While platelet reactivity to certain agonists increases post-cessation, this may not translate to a high thrombotic event rate.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...